{'fraction_non_alphanumeric': 0.025896414342629483, 'fraction_numerical': 0.0, 'mean_word_length': 6.185714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comorbid patient with non-alcoholic fatty liver disease

The article reviews the evidence for an association between non-alcoholic fatty liver disease (NAFLD) and multiple cardiometabolic disorders, including ischemic stroke, insulin resistance, arterial hypertension, dyslipidemia, chronic kidney disease and cardiac arrhythmias and outlines the mechanisms that underpin this relationship. The role of ursodeoxycholic acid, a drug with pleiotropic properties, in the treatment of NAFLD has been shown.